Cabozantinib is also being studied in combination with nivolumab with or without CTLA-4 inhibitor ipilimumab in patients with metastatic genitourinary tumors (NCT02496208), and in a separate trial combining all three aforementioned therapies in rare genitourinary cancers such as penile cancer (NCT03866382). This evidence concerns the gene CTLA4 and urogenital neoplasm.